iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has unveiled a groundbreaking development in cancer treatment with the announcement of PHAGERI...
Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) is forging ahead with its mission to revolutionize cancer treatment, announcing today the acceler...
Pfizer's innovative campaign merges iconic science with a legendary song, captivating millions in the fight against cancer. Rooted in a 175-year legacy of ...
Auron Therapeutics, a pioneering biotechnology firm dedicated to advancing targeted cancer therapies, has announced the selection of its in...
The acquisition encompasses key assets such as pelabresib, a promising late-stage BET inhibitor for myelofibrosis (MF), and tulmimetostat, an early-stage i...
The three partners are joining forces to develop drug candidates that modulate the immune response of cancer patients and block the development of metast...
Hummingbird Diagnostics GmbH, a leader in the analysis of blood-based small RNA (sRNA) for the early detection and characterization of diseases, today anno...
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, de...
First presentation of data from the Phase 3 randomized trial shows statistically significant and clinically meaningful improvement in progression-free surv...
In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide ...
Promega research published today in Nature Communications demonstrates a new potential approach for managing multiple myeloma and other hematological cance...
Kairos Pharma CEO John Yu stated, “The initiation of this trial speaks to the dedication of the Kairos team to execute on its goals to develop therap...
Menarini Silicon Biosystems, a pioneer of liquid biopsy and single-cell technologies, announced the recent publication of the STIC CTC trial data demonstra...
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patien...
© 2024 Biopharma Boardroom. All Rights Reserved.
